Global Market Size, Forecast, and Trend Highlights Over 2025-2037
Predictive Biomarkers Market size was over USD 24.12 billion in 2024 and is poised to exceed USD 226.46 billion by 2037, growing at over 18.8% CAGR during the forecast period i.e., between 2025-2037. In the year 2025, the industry size of predictive biomarkers is evaluated at USD 31.92 billion.
The reason behind the growth is the rising prevalence of chronic diseases, such as cancer, and diabetes across the globe. Predictive biomarkers help in predicting disease progression and assessing the risk of developing certain diseases. For instance, elevated levels of below 4.0 ng/mL prostate-specific antigen in the blood can be a predictive biomarker for prostate cancer and are the most used biomarker in the management of early prostate cancer. According to the data from the World Health Organization (WHO), over 422 million people around the world suffer from diabetes, and it causes about 1.6 million deaths every year, whereas cancer caused over 10 million deaths in 2020.
The growing geriatric population is believed to fuel the market growth since older populations are more prone to diseases such as cardiovascular disease, and also cancer. Hence, the demand for predictive biomarkers is expected to increase to diagnose age-related conditions. According to World Health Organization, the number of people 60 and older in the world is expected to double (2.1 billion) by 2050.
Predictive Biomarkers Sector: Growth Drivers and Challenges
Growth Drivers
-
Expanding Use of Biomarkers for Diagnostic Purposes– The use of biomarkers in numerous sectors, such as personalized medicine, companion diagnostics, disease risk assessment, and drug development, is expected to drive market growth. Predictive biomarkers assist in determining the likelihood of an adverse reaction to a specific treatment modality, its early diagnosis, and its severity. The use of predictive biomarkers might drastically lower healthcare costs since they anticipate whether a given medication will be effective or not, which gives them an edge over predisposition biomarkers.
- Growing Demand for Personalized Medicine- Numerous scientific breakthroughs, and increased demand for the discovery of novel drugs, have led to the rise of personalized medicine. This has significantly driven market growth. Biomarkers are crucial instruments that help in personalizing medical treatments to individual patients which means providing the right treatment to the right patient, at the right dose, at the right time.
Challenges
-
Lack of Efficient Regulatory and Reimbursement Systems- The regulatory and reimbursement processes in the majority of OECD nations are not well suited to handle this new influx of biomarker-based diagnostic tests. Modern biomarker-based diagnostics that produce complex data needing in-depth analysis and interpretation are not well adapted to the regulatory systems now in place as they were designed around simple diagnostic tests. The adoption of these technologies in the clinical arena may be hampered by inadequately designed regulatory and reimbursement systems, which may also serve as a deterrent to further biomarker research. The processes for requesting approval and/or compensation are still being developed at this time.
-
High Capital Investment
-
Technical Difficulties with Collecting and Storing Samples
Predictive Biomarkers Market: Key Insights
| Report Attribute | Details |
|---|---|
|
Base Year |
2024 |
|
Forecast Year |
2025-2037 |
|
CAGR |
18.8% |
|
Base Year Market Size (2024) |
USD 24.12 billion |
|
Forecast Year Market Size (2037) |
USD 226.46 billion |
|
Regional Scope |
|
Predictive Biomarkers Segmentation
Application (Screening, Analysis, Diagnosis, Prediction, Monitoring)
The prediction segment in the predictive biomarkers market is estimated to gain a robust revenue share in the coming years owing to rising demand for measuring the likelihood of results of any treatment procedure. Predictive biomarkers are frequently employed at all stages of the drug discovery and development process to show the connection between the biomarker and treatment outcome and determine whether a disease or condition is present. Owing to their ability to predict whether a patient will respond to a specific chemotherapy, predictive biomarkers aid in the optimization of treatment choices, and are highly used to forecast the effects of treatment on patients, which helps medical professionals to provide specific medications.
End-Use (Hospitals, Specialty Clinics, Research Institutes)
The research institutes segment in the predictive biomarkers market is set to garner a notable share shortly driven by the investment made by various key market players for the creation of novel biomarkers for diagnostic and therapeutic purposes, along with large-scale funds from the government and private organizations which have been given to groups working on the development of new drugs. Research centers contribute to advancements in technology that facilitate biomarker identification associated with specific diseases. Besides this, they conduct clinical trials to assess the utility of predictive biomarkers and promote awareness regarding the benefits of these biomarkers.
Our in-depth analysis of the global market includes the following segments:
|
Indication |
|
|
Application |
|
|
End-Use |
|
Vishnu Nair
Head - Global Business DevelopmentCustomize this report to your requirements — connect with our consultant for personalized insights and options.
Predictive Biomarkers Industry- Regional Synopsis
North American Market Forecast
North America industry is anticipated to account for largest revenue share of 35% by 2037, backed by the advanced research and development activities in the healthcare sector. The U.S. healthcare industry benefits from an effective system of medical research and development and invests significantly in the creation of new diagnostic instruments, which is predicted to spur market expansion. These efforts can lead to the creation of new predictive biomarkers and also increase their availability & accessibility in the region.
APAC Market Statistics
The Asia Pacific Predictive Biomarkers market is estimated to be the second largest, during the forecast timeframe led by increasing spending in healthcare. For instance, health-related spending per person is higher in Australia, Japan, and Singapore, which has led to a rise in the awareness of early disease diagnosis among people living in those countries.
Predictive biomarkers are becoming more widely used in the area as a result, as they aid in disease prevention and early intervention. In Singapore, it is anticipated that by 2030, public and private spending on aged healthcare will increase to over USD 48 billion.
Companies Dominating the Predictive Biomarkers Landscape
- Siemens Healthcare GmbH
- Company Overview
- Business Strategy
- Key Product Offerings
- Financial Performance
- Key Performance Indicators
- Risk Analysis
- Recent Development
- Regional Presence
- SWOT Analysis
- F. Hoffmann-La Roche Ltd
- Epigenomics AG
- Thermo Fisher Scientific Inc.
- Bio-Rad Laboratories, Inc.
- QIAGEN GmbH
- Danaher Corporation
- Biomarker Technologies, Inc.
- Almac Group Limited
- Myriad Genetics, Inc.
- Meso Scale Diagnostics, LLC
Recent Developments
- Myriad Genetics to join hands with Intermountain Precision Genomics to produce genetic testing devices for the global market.
- The Centre for Ocular Research & Education (CORE) and Meso Scale Diagnostics, LLC announced the initiative to use the Meso Scale Discovery platform to identify biomarkers.
Author Credits: Radhika Pawar
- Report ID: 3175
- Published Date: Dec 20, 2024
- Report Format: PDF, PPT
Frequently Asked Questions (FAQ)
Predictive Biomarkers Market Report Scope
FREE Sample Copy includes market overview, growth trends, statistical charts & tables, forecast estimates, and much more.
Connect with our Expert
